Clinical Trials Logo

Clinical Trial Summary

This research study is looking for patients with newly diagnosed acute myeloid leukemia (AML), AML that has returned (relapsed), or it has not responded adequately to previous treatments. Treating certain patients with chemotherapy may not be to their benefit or may cause more harm than benefit. The purpose of this study is to find out what effects (good and bad) erlotinib has on patients and their AML.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01174043
Study type Interventional
Source Indiana University
Contact
Status Completed
Phase Phase 2
Start date July 2010
Completion date March 2012

See also
  Status Clinical Trial Phase
Completed NCT00363974 - Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML Phase 1/Phase 2
Withdrawn NCT02527174 - A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia Phase 1
Recruiting NCT04687657 - Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia Phase 1